Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | CTSC | P53634 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30568865 | 0.80 | MAPT (0.83) | IDH2MAPTLMNAKDM4EAURKA | |
| SCHEMBL28449187 | 0.80 | MAPT (0.83) | IDH2MAPTLMNAKDM4EAURKA | |
| SCHEMBL16014245 | 0.78 | HDAC3 (0.48) | IDH2MAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL17403482 | 0.76 | MAPT (0.52) | MAPTKDM4EAURKAMAPK1ALDH1A1 | |
| SCHEMBL28159939 | 0.75 | MAPT (0.63) | IDH2MAPTLMNAKDM4EAURKA | |
| SCHEMBL15094876 | 0.75 | KDM4E (1.00) | IDH2MAPTLMNAKDM4EAURKA | |
| SCHEMBL1391440 | 0.75 | MAPT (1.00) | IDH2MAPTLMNAKDM4EAURKA | |
| SCHEMBL28458395 | 0.75 | IDH2 (0.86) | IDH2MAPTLMNAKDM4EMAPK1 | |
| SCHEMBL30568833 | 0.75 | IDH2 (1.00) | IDH2MAPTLMNAAURKAMAPK1 | |
| SCHEMBL394991 | 0.75 | KIF11 (0.70) | IDH2MAPTLMNAKDM4EAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | claimed |
| EP-2964620-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | claimed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | claimed |
| WO-2014135423-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | claimed |
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2964620-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| WO-2014135423-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135423-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HAVCR2, UGT1A1, UGT1A3 | IDH2 1004/4885MAPT 4404/4885LMNA 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.